Cure My Disease

Don't miss your cure!

 Log in / Sign up

One magnetic tracer could mark breast tumors and lymph nodes in a single step

NCT ID NCT07844473

Diagnosis Sponsor: King Faisal Specialist Hospital & Research Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 28, 2026 · Last updated Sep 29, 2026 · Updated 1 time

Summary

Researchers test whether a magnetic tracer called Magtrace can do two jobs at once during breast-conserving surgery: outline the area of breast tissue to remove and help find the sentinel lymph node in the armpit. The study enrolls about 35 patients with breast cancer who need bracketing of the excision area and a sentinel node biopsy. A radiologist injects Magtrace around the tumor before surgery, and the surgeon uses a handheld magnetic probe to locate the tracer in the breast and the lymph node.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
super paramagnetic iron oxide (Magtrace), a magnetic tracer injected into the breast
What this could lead to
If it works, this could simplify breast-conserving surgery by using one magnetic tracer to both mark the tumor area and find the sentinel lymph node, potentially lowering costs and avoiding radioactive materials.
What could go wrong
This is a small pilot study testing feasibility, not whether the approach improves cancer outcomes. The tracer may not reliably mark all four bracketing points or the sentinel node, and results may not apply to all breast cancers or surgical settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All patients with breast cancer undergoing breast conserving surgery requiring bracketing of the area of excision (as determined by the multidisciplinary tumor board) and a sentinel lymph node biopsy for axillary staging. Exclusion Criteria: 1. Patients having mastectomy. 2. Patients unfit for breast conserving surgery due to inability to have adjuvant radiotherapy. 3. Patients requiring axillary clearance without sentinel node biopsy. 4. Patient undergoing breast conserving surgery without need for sentinel node biopsy. 5. Patient with metastatic breast cancer requiring palliative surgery for local control. 6. Patients not consenting for research. 7. Patient with allergy to Magtrace.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer (triple negative breast cancer (TNBC)) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm ductal breast carcinoma in situ invasive ductal breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer (triple negative breast cancer (TNBC)) Breast cancer (triple negative type) Breast cancer - ductal carcinoma in situ (DCIS) Breast cancer - infiltrating ductal carcinoma Breast cancer with low to intermediate HER2 expression

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • King Faisal Specialist Hospital and Research Center

    RECRUITING

    Madinah, Saudi Arabia

More trials for these conditions

Other studies related to the condition(s) this trial covers.